Literature DB >> 1379392

Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles.

J Zhou1, X Y Sun, H Davies, L Crawford, D Park, I H Frazer.   

Abstract

Mice of three haplotypes (H-2d, H-2b, and H-2d/b) were immunized with synthetic HPV16 virus-like particles (VLPs), produced using a vaccinia virus doubly recombinant for the L1 and L2 proteins of HPV16. The resultant anti-VLP antisera recognized HPV16 capsids by ELISA assay and baculovirus recombinant HPV16 L1 and L2 protein on immunoblot. Overlapping peptides corresponding to the HPV16 L1 amino acid sequence were used to define the immunoreactive regions of the L1 protein. The majority of the L1 peptides were reactive with IgG from the mice immunized with the synthetic HPV16 capsids. A computer algorithm predicted seven B epitopes in HPV16 L1, five of which lay within peptides strongly reactive with the murine antisera. The murine anti-VLP antisera failed to react with the two peptides recognized by anti-HPV16L1 monoclonal antibodies raised by others against recombinant L1 fusion protein. We conclude that the immunoreactive epitopes of HPV16 defined using virus-like particles differ significantly from those defined using recombinant HPV16 L1 fusion proteins, which implies that such fusion proteins may not be the antigens to look for HPV16L1 specific immune responses in HPV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379392     DOI: 10.1016/0042-6822(92)90582-a

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

Authors:  N Hanumantha Rao; P Baji Babu; L Rajendra; R Sriraman; Yuk-Ying S Pang; John T Schiller; V A Srinivasan
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

2.  The HPV Vaccine Story.

Authors:  Ian H Frazer
Journal:  ACS Pharmacol Transl Sci       Date:  2019-05-29

3.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Authors:  Waleed Mustafa; Paulo Cesar Maciag; Zhen-kun Pan; Jessica R Weaver; Yuhong Xiao; Stuart N Isaacs; Yvonne Paterson
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

5.  Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Authors:  Benjamin Yang; Andrew Yang; Shiwen Peng; Xiaowu Pang; Richard B S Roden; T-C Wu; Chien-Fu Hung
Journal:  Cell Biosci       Date:  2015-06-25       Impact factor: 7.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.